Clene INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
CLNN
Clene INCClene Inc. reports strong clinical data for its lead drug candidate CNM-Au8 in ALS, paving the way for an accelerated FDA approval pathway by mid-2026, despite ongoing financial challenges.
NASDAQ
CLNN
Clene INC10-K: Clene Inc. Reports 2024 Results, Outlines Path to Potential Accelerated Approval for CNM-Au8 in ALS
Clene Inc. details its 2024 financial results and provides an update on its regulatory strategy for CNM-Au8, its lead drug candidate for ALS.
NASDAQ
CLNN
Clene INCClene Inc.'s annual 10-K filing provides a comprehensive overview of the company's capital structure, outstanding warrants, and financial position, highlighting its focus on developing novel nanotherapeutics.